Skip to main content
Premium Trial:

Request an Annual Quote

Response Genetics Prices $4.8M Stock Offering

NEW YORK (GenomeWeb News) – Response Genetics has launched a public offering of nearly 4.5 million shares of its common stock at $1.20 per share.

The Los Angeles-based molecular diagnostics firm said that it expects to raise about $4.8 million in net proceeds, which it will use for working capital and general corporate purposes. It could realize additional proceeds if underwriters of the offering exercise their over-allotment option of 669,666 shares.

The offering price is below Thursday's closing price on the Nasdaq of $1.32, and shares of Response Genetics dropped nearly 11 percent to $1.18 in early Friday trade after the offering was priced.

Last month the firm announced a 24 percent decline in Q3 revenues year over year and ended the quarter with $4.6 million in cash and cash equivalents. It subsequently announced that it had signed on four payors to provide access to the molecular diagnostic firm's tests.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.